Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of *Enterobacteriaceae* and *Pseudomonas aeruginosa*

Adam L. Bailey,^a Tom Armstrong,^b Hari-Prakash Dwivedi,^b Gerald A. Denys,^c Janet Hindler,^d Shelley Campeau,^{d*} Maria Traczewski,^e Romney Humphries,^{d*} Carey-Ann D. Burnham^a

^aDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

^bbioMérieux Inc., Hazelwood, Missouri, USA

^cIndiana University School of Medicine, Indianapolis, Indiana, USA

^dDepartment of Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, California, USA

^eClinical Microbiology Institute, Inc., Wilsonville, Oregon, USA

ABSTRACT Ceftolozane-tazobactam (C/T) is a novel beta-lactam–beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration in 2014 for the treatment of complicated intra-abdominal infections (in combination with metronidazole) and complicated urinary tract infections. In this study, we evaluated the performance of the C/T Etest, a gradient diffusion method. C/T Etest was compared to broth microdilution (BMD) for 51 *Enterobacteriaceae* challenge isolates and 39 *Pseudomonas aeruginosa* challenge isolates at three clinical sites. Essential agreement (EA) between the methods ranged from 47 to 49/51 (92.2 to 96.1%) for the *Enterobacteriaceae*, and categorical agreement (CA) ranged from 49 to 51/51 (96.1 to 100.0%). EA and CA for *P. aeruginosa* were 100% at all sites. The C/T Etest was also compared to BMD for susceptibility testing on 966 clinical isolates (793 *Enterobacteriaceae*, including 167 *Klebsiella pneumoniae* and 159 *Escherichia coli* isolates, in addition to 173 *P. aeruginosa* isolates) collected at four clinical sites. EA between Etest and BMD was 96.9% for *Enterobacteriaceae* isolates and 98.8% for *P. aeruginosa* isolates. Within the *Enterobacteriaceae*, isolates from each species examined had >96% CA. For the clinical isolates, no very major errors were identified but two major errors were found (one for *K. pneumoniae* and one for *Providencia rettgeri*). By BMD, 47.0% of *Enterobacteriaceae* and 46.2% of *P. aeruginosa* challenge strains were nonsusceptible to C/T by CLSI breakpoint criteria; 8.2% of clinical *Enterobacteriaceae* isolates and 12.1% of clinical *P. aeruginosa* isolates were nonsusceptible to C/T by CLSI breakpoint criteria. In conclusion, Etest is accurate and reproducible for C/T susceptibility testing of *Enterobacteriaceae* and *P. aeruginosa*.

KEYWORDS antimicrobial susceptibility testing, Etest, gradient diffusion method, *Pseudomonas aeruginosa*, *Enterobacteriaceae*, ceftolozane-tazobactam

Ceftolozane-tazobactam (C/T) is a new beta-lactam–beta-lactamase inhibitor combination agent that combines a novel oxymino-cephalosporin (ceftolozane) with an established beta-lactamase inhibitor (tazobactam). C/T was approved by the U.S. Food and Drug Administration in 2014 for the treatment of complicated intra-abdominal infections (cIAI, in combination with metronidazole) and complicated urinary tract infections (cUTI) (1). In clinical trials, C/T demonstrated noninferiority to meropenem when used in combination with metronidazole for the treatment of cIAIs (2, 3). Additionally, C/T was noninferior to levofloxacin for the treatment of cUTIs, including pyelonephritis (4), which was mainly attributable to high rates of levofloxacin-resistant isolates among cUTI-causing bacteria (5,

Received 29 April 2018 Returned for
modification 23 May 2018 Accepted 25 June
2018

Accepted manuscript posted online 5 July
2018

Citation Bailey AL, Armstrong T, Dwivedi H-P, Denys GA, Hindler J, Campeau S, Traczewski M, Humphries R, Burnham C-AD. 2018. Multicenter evaluation of the Etest gradient diffusion method for ceftolozane-tazobactam susceptibility testing of *Enterobacteriaceae* and *Pseudomonas aeruginosa*. J Clin Microbiol 56:e00717-18. <https://doi.org/10.1128/JCM.00717-18>.

Editor Nathan A. Ledebore, Medical College of Wisconsin

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Carey-Ann D. Burnham, cburnham@wustl.edu.

* Present address: Romney Humphries and Shelley Campeau, Accelerate Diagnostics, Tucson, Arizona, USA.

FIG 1 Interpretation of Etest results. C/T Etest strips were placed onto Mueller-Hinton agar plates that had been inoculated using a sterile cotton swab moistened with a 0.5 McFarland suspension. Plates were then read after incubation in ambient air at $35 \pm 2^\circ\text{C}$ for 16 to 20 h. The MIC result was read where the zone of inhibition ellipse intersected the Etest strip; if the ellipse intersected between two MIC values, the higher of the two values was reported. Hazy growth and colonies within the ellipse were counted as true growth.

6). *In vitro*, C/T inhibits the growth of a high percentage of bacterial isolates from the medically important *Enterobacteriaceae* family and *Pseudomonas aeruginosa*, outperforming several current first-line antibiotics for the treatment of multidrug-resistant (MDR) organisms (3, 7–14). Nevertheless, resistance to C/T has been observed, emphasizing the need for C/T susceptibility testing in clinical microbiology laboratories (15–17). Here we report a multicenter evaluation of a C/T Etest (bioMérieux, Durham, NC) which was recently cleared by the U.S. FDA for *in vitro* diagnostic use (18).

MATERIALS AND METHODS

Ethics statement. Prior to study initiation, each study site acquired approval or waiver from their respective institutional review board.

Quality control. The following isolates were used for quality control (QC) of the C/T Etest and broth microdilution (BMD) each day of testing: *Escherichia coli* ATCC 25922, *Escherichia coli* ATCC 35218, *Pseudomonas aeruginosa* ATCC 27853, *Klebsiella pneumoniae* ATCC 700603, and *Staphylococcus aureus* ATCC 29213 (BMD only), using Clinical and Laboratory Standards Institute (CLSI) QC ranges for these strains. Quality control results were within acceptable limits for 99% of quality control tests performed on each quality control organism, and quality control was verified to be within normal limits on every day that comparative analysis was performed (i.e., challenge and clinical studies). Quality control testing was performed a minimum of 20 times at each site.

Setting. Testing was performed at the Clinical Microbiology Institute (CMI; Portland, OR), the University of California-Los Angeles (UCLA; Los Angeles, CA) Health System, the University of Indiana (WU; Indianapolis, IN), Washington University in St. Louis School of Medicine (WU; St. Louis, MO), and bioMérieux St. Louis Clinical Affairs (St. Louis, MO).

Clinical isolates and C/T susceptibility testing. A combination of fresh and previously frozen clinical isolates was evaluated in this study: *Enterobacteriaceae* (422/793 fresh; 371/793 frozen) and *P. aeruginosa* (109/173 fresh; 64/173 frozen). Isolates were recovered and identified from patient specimens using standard-of-care culture media and procedures at each study site. For C/T susceptibility testing using the Etest, Mueller-Hinton agar II plates (Remel Inc., San Diego, CA) were inoculated with a sterile cotton swab moistened with a 0.5 McFarland suspension and the Etest strip was placed on the plate with an applicator or forceps. Plates were incubated in ambient air at $35 \pm 2^\circ\text{C}$ and read at 16 to 20 h postinoculation. For BMD, 0.01 ml of a 0.5 McFarland solution that had been diluted 1:300 was inoculated into 95 wells of a 96-well plate using a 96-well-plate inoculator. BMD plates containing 0.1 ml of diluted C/T solutions were prepared by bioMérieux according to processes described in CLSI documents M100 and M7 (19, 20) using Becton Dickinson Mueller-Hinton medium and stored at -70°C until use. All BMD plates were read following 16 to 20 h of incubation in ambient air at $35 \pm 2^\circ\text{C}$. Directions for reading the C/T Etest (i.e., the Etest reading guide and the supplemental package insert) were provided to sites. These materials included instruction on interpreting hazes (which were included as growth with the exception of swarming by *Proteus* species) and colonies within the zone (which were counted as true growth). Magnifying lenses were also supplied to each site, but magnification was not required for reading of Etest results. An example of Etest results for the species used in this study can be found in Fig. 1.

Reproducibility and challenge testing. Reproducibility testing was performed using a set of 25 on-scale strains (i.e., strains that had expected MICs falling within the measurable range of the Etest device); all strains were tested at three clinical sites using the Etest exclusively. An inoculum density

TABLE 1 Reproducibility of C/T Etest

Organism	MIC ($\mu\text{g/ml}$)				DD ^a from the median/mode					
	Site A	Site B	Site C	Mode/median	Off-scale	−2	−1	0	1	2
<i>E. cloacae</i>	16	16	32	16				2	1	
<i>E. coli</i>	1	1	2	1				2	1	
	1	2	8	2 ^b			1	1		1
	0.5	0.5	1	0.5				2	1	
	0.5	0.5	1	0.5				2	1	
	0.125	0.125	0.125	0.125				3		
	2	2	2	2				3		
<i>K. oxytoca</i>	0.125	0.125	0.125	0.125				3		
	4	2	4	4			1	2		
	0.5	0.5	0.5	0.5				3		
<i>K. pneumoniae</i>	1	0.5	2	1 ^b			1	1	1	
	64	256	128	128 ^b			1	1	1	
	1	2	1	1				2	1	
	32	256	64	64 ^b			1	1		1
	2	1	1	1				2	1	
<i>P. aeruginosa</i>	0.5	0.25	0.25	0.25				2	1	
	128	128	256	128				2	1	
	64	64	128	64				2	1	
	1	1	2	1				2	1	
	0.5	0.5	1	0.5				2	1	
	2	2	4	2				2	1	
	1	1	1	1				3		
	1	1	1	1				3		
	0.5	0.5	0.5	0.5				3		
	0.5	0.5	0.5	0.5				3		
Total					0	0	5	54	14	2

^aDD, double dilution.^bMedian value.

check was performed on all isolates. Challenge testing was performed at three clinical sites using 90 frozen stock organisms provided by bioMérieux. All challenge isolates were tested using Etest and BMD. To derive the MIC for BMD in the challenge study, this trial used a voted reference result as the basis for comparison. The voted reference was derived by comparing the BMD results from all three sites for each isolate. The voted reference result was either a consensus result, the best two of three, or a modal value. In situations where all three reference results were the same, the consensus result was used.

Interpretation of results and data analysis. Results from all isolates tested for C/T susceptibility using the Etest and BMD methods were included in the analysis. Essential agreement (EA) was defined as agreement between the two methods ± 1 doubling dilution and was calculated by the Biomath team at bioMérieux. Etest results were rounded up to the nearest dilution that was performed for BMD for this calculation. Categorical agreement (CA) between the Etest and BMD, as well as very major, major, and minor error evaluation, was determined using CLSI breakpoint criteria unless otherwise specified.

RESULTS

Reproducibility of C/T Etest. We used isolates of *Enterobacter cloacae* ($n = 1$), *Escherichia coli* ($n = 7$), *Klebsiella oxytoca* ($n = 3$), *Klebsiella pneumoniae* ($n = 5$), and *Pseudomonas aeruginosa* ($n = 9$) to evaluate the reproducibility of the Etest at three sites: the Clinical Microbiology Institute (CMI; Portland, OR), the University of California-Los Angeles (UCLA; Los Angeles, CA) Health System, and Washington University in St. Louis School of Medicine (WU). The MICs of C/T required to inhibit growth of each isolate were compared across sites (Table 1), showing that 73/75 (97.3%) isolates tested fell within ± 1 doubling dilution of the mode (or the median, if no mode existed).

C/T Etest challenge study. To examine the accuracy of the Etest, we compared MICs derived by C/T Etest to MICs derived by BMD for 51 *Enterobacteriaceae* and 39 *P. aeruginosa* strains at CMI, UCLA, and WU (see Table S1 in the supplemental material for details on each isolate). Among the *Enterobacteriaceae* isolates evaluated, 23/51 (45%) were resistant to C/T by BMD using the CLSI breakpoints (susceptible [S], $\leq 2/4 \mu\text{g/ml}$;

TABLE 2 Challenge study of C/T Etest^a

Organism(s)	Site	No. of isolates	No. with indicated result by BMD			Performance, no. (%)				
			S	I	R	EA	CA	VMEs	MEs	mEs
<i>Enterobacteriaceae</i>	A	51	27	1	23	47 (92.2)	51 (100)	0 (0)	0 (0)	0 (0)
	B	51	27	1	23	49 (96.1)	49 (96.1)	0 (0)	1 (3.7)	1 (2.0)
	C	51	27	1	23	48 (94.1)	49 (96.1)	1 (4.3)	0 (0)	1 (2.0)
<i>P. aeruginosa</i>	A	39	21	0	18	39 (100)	39 (100)	0 (0)	0 (0)	0 (0)
	B	39	21	0	18	39 (100)	39 (100)	0 (0)	0 (0)	0 (0)
	C	39	21	0	18	39 (100)	39 (100)	0 (0)	0 (0)	0 (0)

^aR, resistant; I, intermediate; S, susceptible; EA, essential agreement (MIC $\pm$ 1 doubling dilution); CA, categorical agreement; VMEs, very major errors; MEs, major errors; mEs, minor errors.

intermediate [I], 4/4 $\mu\text{g/ml}$; resistant [R], $\geq 8/4 \mu\text{g/ml}$), while 27/51 (53%) were susceptible and 1/51 was intermediate (Table 2). Similarly, 18/39 (46%) *P. aeruginosa* strains evaluated were resistant and 21/39 (54%) were susceptible by BMD using CLSI breakpoint criteria (S, $\leq 4/4 \mu\text{g/ml}$; I, $8/4 \mu\text{g/ml}$; R, $\geq 16/4 \mu\text{g/ml}$). Essential agreement (EA) between the C/T Etest and BMD methods ranged from 47/51 (92.2%) to 49/51 (96.1%) for the *Enterobacteriaceae* species; categorical agreement (CA) ranged from 49/51 (96.1%) to 51/51 (100%), with 1 very major error, 1 major error, and 2 minor errors identified. EA and CA for *P. aeruginosa* were 100% at all sites.

Clinical performance of C/T Etest. We examined the performance of the C/T Etest at five sites: CMI, UCLA, WU, Indiana University School of Medicine (Indianapolis, IN), and bioMérieux St. Louis Clinical Affairs (St. Louis, MO). A combined total of 966 clinical isolates were evaluated across the five study sites, including 793 strains of *Enterobacteriaceae* and 173 isolates of *P. aeruginosa*. The majority of *Enterobacteriaceae* (428/793 [54.0%]) were isolated from urine, while respiratory specimens were the most common source of *P. aeruginosa* isolates (52/173 [30.1%]) (see Table S2 for the specimen type from which each isolate was recovered and the corresponding MIC of each isolate). Per CLSI breakpoints for the *Enterobacteriaceae*, 56/793 (7.1%) of patient isolates were resistant to C/T by BMD, 728/793 (91.8%) were susceptible, and 9/793 (1.1%) had MICs that fell within the intermediate category (Table 3). The species with the highest percentage of resistant isolates were *E. cloacae* (8/53 [15.1%]) and *K. oxytoca* (7/58 [12.1%]). For *P. aeruginosa*, 17/173 (9.8%) of patient isolates were resistant by BMD using CLSI breakpoints, while 152/173 (87.9%) of isolates were susceptible and 4/173 (2.3%) were of intermediate susceptibility. EA between BMD and Etest was 768/793 (98.5%) for *Enterobacteriaceae* collectively (Fig. 2A), with the EA for each species within the *Enterobacteriaceae* ranging from 93.4% (*K. pneumoniae*) to 100%. CA for *Enterobacteriaceae* isolates collectively was 781/793 (98.5%), with the CA for each species within the *Enterobacteriaceae* ranging from 96.2% (*E. cloacae*) to 100%. For *P. aeruginosa*, EA and CA of the C/T Etest versus BMD were 171/173 (98.8%) and 172/173 (99.4%), respectively (Table 3; Fig. 2B). No very major errors were identified in our clinical study. However, two major errors were found: one *K. pneumoniae* isolate with an Etest MIC of 64 $\mu\text{g/ml}$ and a BMD MIC of 0.5 $\mu\text{g/ml}$ and one *P. rettgeri* isolate with an Etest MIC of 8 $\mu\text{g/ml}$ and a BMD MIC of 2 $\mu\text{g/ml}$. Eleven minor errors were also identified: 10 from *Enterobacteriaceae* isolates and 1 from a *P. aeruginosa* isolate, with no obvious bias toward one pattern of minor error.

We also analyzed the categorical interpretation of our clinical data using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, which are more conservative than CLSI breakpoints for *Enterobacteriaceae* and do not include an intermediate category (for *Enterobacteriaceae*, S, $\leq 1/4 \mu\text{g/ml}$, and R, $> 1/4 \mu\text{g/ml}$; for *P. aeruginosa*, S, $\leq 4/4 \mu\text{g/ml}$, and R, $> 4/4 \mu\text{g/ml}$). Using EUCAST breakpoints, CA was higher for both *Enterobacteriaceae* (785/793 [99.0%]) and *P. aeruginosa* (173/173 [100%]) than CLSI breakpoints. However, more very major ($n = 3$) and major errors ($n = 5$) were found when using EUCAST criteria (Table 3).

TABLE 3 Clinical performance of C/T Etest

Organism(s)	No. of isolates	No. (%) matching CLSI breakpoint criteria								No. (%) matching EUCAST breakpoint criteria							
		Result by BMD				Performance				Result by BMD				Performance			
		S	I	R	EA	CA	VMEs	MEs	mEs	S	R	EA	CA	VMEs	MEs		
<i>Enterobacteriaceae</i> (total)	793	728 (91.8)	9 (1.1)	56 (7.1)	768 (96.8)	781 (98.5)	0 (0)	2 (0.3)	10 (1.3)	718 (90.5)	75 (9.5)	768 (96.8)	785 (99.0)	3 (4.0)	5 (0.7)		
<i>Citrobacter koseri</i>	48	48 (100)	0 (0)	0 (0)	48 (100)	48 (100)	0 (ND ^a)	0 (0)	0 (0)	47 (97.9)	1 (2.1)	48 (100)	48 (100)	0 (0)	0 (0)		
<i>Enterobacter cloacae</i>	53	44 (83.0)	1 (1.9)	8 (15.1)	51 (96.2)	51 (96.2)	0 (0)	0 (0)	2 (3.8)	44 (83.0)	9 (17.0)	51 (96.2)	52 (98.1)	0 (0)	1 (2.3)		
<i>Escherichia coli</i>	159	146 (91.8)	1 (0.6)	12 (7.5)	153 (96.2)	159 (100)	0 (0)	0 (0)	2 (1.3)	146 (91.8)	14 (8.8)	153 (96.2)	158 (99.4)	0 (0)	1 (0.7)		
<i>Klebsiella oxytoca</i>	58	52 (89.7)	1 (1.7)	7 (12.1)	56 (96.6)	58 (100)	0 (0)	0 (0)	0 (0)	50 (86.2)	9 (15.5)	56 (96.6)	57 (98.3)	0 (0)	1 (2.0)		
<i>Klebsiella pneumoniae</i>	167	153 (91.6)	1 (0.6)	13 (7.8)	156 (93.4)	164 (98.2)	0 (0)	1 (0.7)	2 (1.2)	151 (90.4)	16 (9.6)	156 (93.4)	165 (98.8)	1 (6.3)	1 (0.7)		
<i>Morganella morganii</i>	50	45 (90.0)	0 (0)	5 (10.0)	50 (100)	50 (100)	0 (0)	0 (0)	0 (0)	45 (90.0)	5 (10.0)	50 (100)	49 (98.0)	0 (0)	1 (2.2)		
<i>Proteus mirabilis</i>	65	62 (95.4)	1 (1.5)	2 (3.1)	64 (98.5)	64 (98.5)	0 (0)	0 (0)	1 (1.5)	61 (93.8)	4 (6.2)	64 (98.5)	64 (98.5)	0 (0)	0 (0)		
<i>Proteus vulgaris</i>	49	48 (98.0)	1 (2.0)	0 (0)	48 (98.0)	48 (98.0)	0 (ND)	0 (0)	1 (2.0)	3 (6.1)	46 (93.9)	48 (98.0)	47 (95.9)	2 (4.3)	0 (0)		
<i>Providencia rettgeri</i>	40	39 (97.5)	0 (0)	1 (2.5)	39 (97.5)	39 (97.5)	0 (0)	1 (2.6)	0 (0)	38 (95.0)	2 (5.0)	39 (97.5)	40 (100)	0 (0)	0 (0)		
<i>Providencia stuartii</i>	42	34 (81.0)	3 (7.1)	5 (11.9)	40 (95.2)	41 (97.6)	0 (0)	0 (0)	1 (2.4)	34 (81.0)	8 (19.0)	40 (95.2)	42 (100)	0 (0)	0 (0)		
<i>Serratia liquefaciens</i>	10	10 (100)	0 (0)	0 (0)	10 (100)	10 (100)	0 (ND)	0 (0)	0 (0)	10 (100)	0 (0)	10 (100)	10 (100)	0 (ND)	0 (0)		
<i>Serratia marcescens</i>	52	47 (90.4)	0 (0)	5 (9.6)	52 (100)	51 (98.1)	0 (0)	0 (0)	1 (1.9)	46 (88.5)	6 (11.5)	52 (100)	52 (100)	0 (0)	0 (0)		
<i>Pseudomonas aeruginosa</i>	173	152 (87.9)	4 (2.3)	17 (9.8)	171 (98.8)	172 (99.4)	0 (0)	0 (0)	1 (0.6)	152 (87.9)	21 (12.1)	171 (98.8)	173 (100)	0 (0)	0 (0)		

^aND, not defined.

A. C/T Etest vs. reference method for *Enterobacteriaceae* (n = 793)

B. C/T Etest vs. reference method for *Pseudomonas aeruginosa* (n = 173)

FIG 2 Correlation of C/T MICs from Etest and BMD. Clinical isolates identified as *Enterobacteriaceae* (n = 793) (A) or *P. aeruginosa* (B) (n = 173) were subjected to C/T susceptibility testing by Etest and BMD. The numbers of isolates with MICs corresponding to each test method are shown, with darker squares corresponding to MIC values displayed by a larger number of isolates. CLSI breakpoints are shown as dark solid lines, with their respective interpretation for each method shown to the left and top of the plot.

DISCUSSION

C/T is a novel beta-lactam–beta-lactamase inhibitor combination that was developed for the treatment of infections with multidrug-resistant Gram-negative bacteria. In this study, C/T susceptibility testing was performed on a large number of Gram-negative bacterial isolates at multiple study sites across a large geographic distribution in the continental United States. We found that the MIC values derived by the Etest for C/T correlated well with MIC values obtained by BMD for both *Enterobacteriaceae* and *P. aeruginosa*, exceeding the >90% threshold of EA required by the FDA. Additionally, we identified very few categorical and very major errors using CLSI breakpoint criteria for *Enterobacteriaceae* and *P. aeruginosa*.

Despite growing interest in the use of C/T by physicians (21), only a limited number of studies have evaluated the performance of alternatives to BMD for C/T susceptibility testing. Among these studies, a considerable range of performance has been observed for a variety of C/T susceptibility testing devices. For example, a research-use-only (RUO) version of the Etest performed poorly compared to BMD for susceptibility testing

of a small number of meropenem-nonsusceptible *P. aeruginosa* isolates in Michigan (22), but these data were later questioned when a follow-up to this study suggested favorable performance characteristics for the C/T Etest (<96% EA and CA) (23). Although our study did not produce any very major errors in the clinical isolate portion of the study, one very major error was identified in the challenge set study. Interestingly, the isolate for which this error occurred had Etest and BMD results that were internally consistent at each site; however, this isolate had MICs in the susceptible range at one site but MICs that were resistant at the two other sites. Therefore, when the voted BMD reference value was generated, this created a very major error for the one site at which the isolate tested as susceptible. Given the consistency of test results for this isolate within each site, it appears that this error was not due to a failure of the test device but rather an artifact of the data analysis in combination with the possibility of the loss of a resistance plasmid.

Other devices that use gradient diffusion (e.g., Liofilchem MIC test strip) for C/T testing have been shown to have unacceptably high error rates (23). These discrepancies could reflect the fact that interpretation of MIC results from gradient diffusion devices can be more subjective than BMD results. In addition, the population distribution of many Gram-negative species falls near the breakpoint for this antimicrobial agent, which can be challenging for accurate categorical interpretation. However, various degrees of performance have also been reported for disk diffusion assays for C/T disks (23–25). Despite these limitations, in most clinical laboratory settings, C/T susceptibility testing options like gradient diffusion that are more accessible than BMD are critically needed because approximately 10% of infections for which C/T therapy is indicated are caused by a C/T-resistant organism and therefore susceptibility testing is needed to optimize therapy and antimicrobial stewardship (6, 7, 9–17, 24, 26, 27). Indeed, C/T resistance and treatment failures have already been described and appear to be acquired/mediated via a variety of mechanisms, emphasizing the need for widely accessible phenotypic C/T susceptibility testing (8, 11, 24, 28–30).

This study has limitations, including the small number of isolates for some of the specific species evaluated and the lack of resistant isolates for some species tested. The strengths of this study include reference BMD as a reference method, standardization of preparation of the BMD panels, the large number of isolates evaluated, and the multicenter nature of the study.

In conclusion, testing a large number of clinical strains from different geographic regions within the United States, we found that the bioMérieux C/T Etest is a reproducible and accurate method for C/T susceptibility testing of *Enterobacteriaceae* and *P. aeruginosa*.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/JCM.00717-18>.

SUPPLEMENTAL FILE 1, XLSX file, 0.1 MB.

SUPPLEMENTAL FILE 2, XLSX file, 0.1 MB.

ACKNOWLEDGMENTS

This study was funded by bioMérieux. We thank Meghan Wallace, Sheri Garret, and Paul Magnano for excellent technical assistance with this study.

This study was funded by bioMérieux.

REFERENCES

1. US FDA. 2014. Drug approval package for Zerbaxa (ceftolozane/tazobactam). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf.
2. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. 2015. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-clAI). *Clin Infect Dis* 60:1462–1471. <https://doi.org/10.1093/cid/civ097>.
3. Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J. 2016. Characteristics and outcomes of complicated intra-abdominal infections involving *Pseudomonas aeruginosa* from a randomized, double-blind,

- phase 3 ceftolozane-tazobactam study. *Antimicrob Agents Chemother* 60:4387–4390. <https://doi.org/10.1128/AAC.03074-15>.
4. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. 2015. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet* 385: 1949–1956. [https://doi.org/10.1016/S0140-6736\(14\)62220-0](https://doi.org/10.1016/S0140-6736(14)62220-0).
 5. Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ. 2016. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. *J Antimicrob Chemother* 71:2014–2021. <https://doi.org/10.1093/jac/dkw053>.
 6. Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS. 2017. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae*: a pooled analysis of phase 3 clinical trials. *J Antimicrob Chemother* 72:268–272. <https://doi.org/10.1093/jac/dkw374>.
 7. Goodlet KJ, Nicolau DP, Nailor MD. 2017. An *in vitro* comparison of ceftolozane/tazobactam compared to traditional beta-lactams as an alternative to combination antimicrobial therapy for *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 61:e01350-17. <https://doi.org/10.1128/AAC.01350-17>.
 8. Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martínez-Martínez L, Horcjada JP, Oliver A. 2017. Genomics and susceptibility profiles of extensively drug-resistant *Pseudomonas aeruginosa* from Spain. *Antimicrob Agents Chemother* 61:e01589-17. <https://doi.org/10.1128/AAC.01589-17>.
 9. Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M. 2017. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* causing healthcare-associated infections in Australia and New Zealand: report from an antimicrobial surveillance program (2013–2015). *J Glob Antimicrob Resist* 10:186–194. <https://doi.org/10.1016/j.jgar.2017.05.025>.
 10. Seifert H, Körber-Irrgang B, Kresken M, German Ceftolozane/Tazobactam Study Group. 2018. In-vitro activity of ceftolozane/tazobactam against *Pseudomonas aeruginosa* and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. *Int J Antimicrob Agents* 51: 227–234. <https://doi.org/10.1016/j.ijantimicag.2017.06.024>.
 11. Grupper M, Sutherland C, Nicolau DP. 2017. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible *Pseudomonas aeruginosa* from blood, respiratory tract, and wounds. *Antimicrob Agents Chemother* 61:e00875-17. <https://doi.org/10.1128/AAC.00875-17>.
 12. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. 2017. Ceftolozane-tazobactam activity against *Pseudomonas aeruginosa* clinical isolates from U.S. hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. *Antimicrob Agents Chemother* 61:e00465-17. <https://doi.org/10.1128/AAC.00465-17>.
 13. Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Evaluation of the *in vitro* activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant *Pseudomonas aeruginosa* isolates. *Antimicrob Agents Chemother* 60:3227–3231. <https://doi.org/10.1128/AAC.02969-15>.
 14. Gonzalez MD, McMullen AR, Wallace MA, Crotty MP, Ritchie DJ, Burnham CA. 2017. Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of β -lactam-resistant Gram-negative bacteria. *Ann Lab Med* 37:174–176. <https://doi.org/10.3343/alm.2017.37.2.174>.
 15. Sutherland CA, Nicolau DP. 2015. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* from US hospitals. *Clin Ther* 37:1564–1571. <https://doi.org/10.1016/j.clinthera.2015.05.501>.
 16. Walky A, Karlowsky JA, Adam H, Baxter M, Lagacé-Wiens P, Hoban DJ, Zhanel GG. 2013. *In vitro* activity of ceftolozane-tazobactam against *Pseudomonas aeruginosa* isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. *Antimicrob Agents Chemother* 57:5707–5709. <https://doi.org/10.1128/AAC.01404-13>.
 17. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and *Pseudomonas aeruginosa* with various resistance patterns isolated in U.S. hospitals (2011–2012). *Antimicrob Agents Chemother* 57:6305–6310. <https://doi.org/10.1128/AAC.01802-13>.
 18. US Food and Drug Administration. 2017. Etest® ceftolozane/tazobactam notification of marketing approval to bioMérieux. https://www.accessdata.fda.gov/cdrh_docs/pdf17/K170670.pdf.
 19. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M7-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
 20. Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing, 28th ed. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.
 21. Sucher AJ, Chahine EB, Cogan P, Fete M. 2015. Ceftolozane/tazobactam: a new cephalosporin and β -lactamase inhibitor combination. *Ann Pharmacother* 49:1046–1056. <https://doi.org/10.1177/1060028015593293>.
 22. Flynt LK, Veve MP, Samuel LP, Tibbetts RJ. 2017. Comparison of Etest to broth microdilution for testing of susceptibility of *Pseudomonas aeruginosa* to ceftolozane-tazobactam. *J Clin Microbiol* 55:334–335. <https://doi.org/10.1128/JCM.01920-16>.
 23. Humphries RM, Hindler JA, Magnano P, Wong-Beringer A, Tibbetts R, Miller SA. 2018. Performance of ceftolozane-tazobactam Etest, MIC test strips, and disk diffusion compared to reference broth microdilution for β -lactam-resistant *Pseudomonas aeruginosa* isolates. *J Clin Microbiol* 56:e01633-17. <https://doi.org/10.1128/JCM.01633-17>.
 24. Schaumburg F, Bletz S, Mellmann A, Becker K, Idelevich EA. 2017. Susceptibility of MDR *Pseudomonas aeruginosa* to ceftolozane/tazobactam and comparison of different susceptibility testing methods. *J Antimicrob Chemother* 72:3079–3084. <https://doi.org/10.1093/jac/dkx253>.
 25. Shields RK, Clancy CJ, Pasculle AW, Press EG, Haidar G, Hao B, Chen L, Kreiswirth BN, Nguyen MH. 2018. Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and *Pseudomonas aeruginosa*. *J Clin Microbiol* 56:e01093-17. <https://doi.org/10.1128/JCM.01093-17>.
 26. Alatoon A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Moity M, Bonilla MF, Nusair A, Mirza I. 2017. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. *Int J Infect Dis* 62: 39–43. <https://doi.org/10.1016/j.ijid.2017.06.007>.
 27. Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, Chaudhry A, Pike R, Staves P, Woodford N, BSACRSSC. 2017. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, *Pseudomonas aeruginosa* and non-fermenters from the British Isles. *J Antimicrob Chemother* 72:2278–2289. <https://doi.org/10.1093/jac/dkx136>.
 28. MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L. 2017. Emergence of ceftolozane-tazobactam-resistant *Pseudomonas aeruginosa* during treatment is mediated by a single AmpC structural mutation. *Antimicrob Agents Chemother* 61:e01183-17. <https://doi.org/10.1128/AAC.01183-17>.
 29. Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez JL, Oliver A. 2017. *In vivo* emergence of resistance to novel cephalosporin- β -lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 β -lactamase (OXA-539) in sequence type 235 *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 61:e01117-17. <https://doi.org/10.1128/AAC.01117-17>.
 30. Gangcuangco LM, Clark P, Stewart C, Miljkovic G, Saul ZK. 2016. Persistent bacteremia from *Pseudomonas aeruginosa* with *in vitro* resistance to the novel antibiotics ceftolozane-tazobactam and ceftazidime-avibactam. *Case Rep Infect Dis* 2016:1520404.